Measurement of Substance P in Saliva of Low Back Pain Patients
NCT ID: NCT00735735
Last Updated: 2019-08-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
NA
40 participants
INTERVENTIONAL
2009-02-28
2014-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Influence of Different Factors on Workers' Disability Due to Low Back Pain
NCT00667316
The Influence of Coping Strategies and Catastrophizing on Patients With Back and Neck Pain
NCT00502333
Immediate Exercise-Induced Hypoalgesia in Patients With Chronic Low Back Pain
NCT05077566
A Retrospective Study to Identify New "Omics" Biomarkers of Chronic/Persistent Low Back Pain
NCT02037789
Open Label Placebo in the Treatment of Low Back Pain
NCT02022124
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
PARALLEL
DIAGNOSTIC
SINGLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
The taking of a saliva sample from each subject.
After taking the sample, the saliva will be transferred via a pipette to a clean tube which will be labeled with the subject's name, the date and the hour. Once a month the tubes will be sent to the collaborating laboratory for analysis.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* A pain level of 6 or greater on the PI-NRS scale (0=no pain, 10= worst pain possible)
* Seen at the Unit between 9 and 13 hours (due to the circadian rhythm of Substance P in saliva and to avoid great variability in the results)
For healthy subjects:
* Volunteers with no pain (anywhere)
* That in the past year have had no more than 40 days with pain, and no episode of more than 7 days of continuous pain.
Exclusion Criteria
18 Years
80 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Kovacs Foundation
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Francisco M. Kovacs
Director of Scientific Department, Kovacs Foundation
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Francisco M Kovacs, MD, PhD
Role: STUDY_DIRECTOR
Kovacs Foundation, Palma de Mallorca, 07012, Spain
Mario Gestoso, MD
Role: PRINCIPAL_INVESTIGATOR
Kovacs Foundation,Palma de Mallorca, Spain
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Kovacs Foundation
Palma de Mallorca, Balearic Islands, Spain
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
LeVasseur SA, Gibson SJ, Helme RD. The measurement of capsaicin-sensitive sensory nerve fiber function in elderly patients with pain. Pain. 1990 Apr;41(1):19-25. doi: 10.1016/0304-3959(90)91104-Q.
Morton CR, Hutchison WD. Release of sensory neuropeptides in the spinal cord: studies with calcitonin gene-related peptide and galanin. Neuroscience. 1989;31(3):807-15. doi: 10.1016/0306-4522(89)90443-0.
Kowalski ML, Sliwinska-Kowalska M, Kaliner MA. Neurogenic inflammation, vascular permeability, and mast cells. II. Additional evidence indicating that mast cells are not involved in neurogenic inflammation. J Immunol. 1990 Aug 15;145(4):1214-21.
Thomas KL, Andrews PV, Khalil Z, Helme RD. Substance P induced hydrolysis of inositol phospholipids in rat skin in an in vivo model of inflammation. Neuropeptides. 1989 Apr;13(3):191-6. doi: 10.1016/0143-4179(89)90091-7.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
FK 26
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.